Retrospective analysis of imaging modalities acquired during clinical diagnosis of patients with clinical suspected neurodegenerative Parkinsonian syndrome

Retrospective analysis of imaging modalities acquired during clinical diagnosis of patients with clinical suspected neurodegenerative Parkinsonian syndrome - MOPET

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016920

Enrollment

Registered

2019-03-18

Start date

2019-03-31

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20

Interventions

Group 1: Quantitative analysis of cMRI and/or OCT and/or tau-PET in patients with probable or possible progressive supranuclear palsy Group 2: Quantitative analysis of cMRI and/or OCT and/or tau-PET i

Eligibility

Sex/Gender

All

Age

40 Years to 90 Years

Inclusion criteria

Inclusion criteria: clinical suspected neurodegenerative Parkinsonian Syndrome and acquisition of at least one of the following modalities: cMRI, OCT, tau-PET

Exclusion criteria

Exclusion criteria: other non-neurodegenerative CNS diseases like glioma or stroke

Design outcomes

Primary

Measure	Time frame
For patients with cMRT the midbrain diameter and the midbrain to pons ratio will be acquired. For patients with OCT the thickness of retinal layers will be accessed. For patients with tau-PET the regional signal in defined target regions (midbrain, globus pallidus, nucleus dentatus, frontal cortex) will be quantified. The quantification will be performed retrospectively and linked to the acqusition date. Specific software will be used for quantification (i.e. PMOD Technologies, Basel, Switzerland). The primary endpoint consists in correlation of cMRI, OCT, and tau-PET quantification with disease severity for patients with Progressive Supranuclear Palsy.	—

Measure

Time frame

For patients with cMRT the midbrain diameter and the midbrain to pons ratio will be acquired. For patients with OCT the thickness of retinal layers will be accessed. For patients with tau-PET the regional signal in defined target regions (midbrain, globus pallidus, nucleus dentatus, frontal cortex) will be quantified. The quantification will be performed retrospectively and linked to the acqusition date. Specific software will be used for quantification (i.e. PMOD Technologies, Basel, Switzerland). The primary endpoint consists in correlation of cMRI, OCT, and tau-PET quantification with disease severity for patients with Progressive Supranuclear Palsy.

—

Secondary

Measure	Time frame
Quantification of cMRI, OCT, and tau-PET will be compared between patients with probable and possible Progressive Supranuclear Palsy, patients with probable tau-negative Parkinsonian syndrome and healthy controls.	—

Countries

Germany

Contacts

Public ContactMatthias Brendel

Klinik und Poliklinik für Nuklearmedizin, LMU München

matthias.brendel@med.uni-muenchen.de089440074650

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026